“Further investigation is needed to optimize selection between multiple available treatment strategies for patients with PD-L1–high NSCLC,” write Charu Aggarwal and colleagues from the University of Pennsylvania in Philadelphia, USA, in JAMA Oncology .

Commenting on the findings, Charu Aggarwal, MD, MPH, Leslye M Heisler Associate Professor of Lung Cancer Excellence (University of Pennsylvania, Philadelphia, USA), told medwireNews that “[b]ased on these observations, baseline echocardiogram and serial monitoring is advised.”

Charu Aggarwal, from the University of Pennsylvania in Philadelphia, USA, and co-authors propose in JCO Oncology Practice that the “general principles of lung cancer treatment continue to be followed in most cases where delays could result in rapid cancer progression.”

Management of EGFR -mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Management of EGFR -mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Editorialists Charu Aggarwal and Corey Langer, both from the University of Pennsylvania in Philadelphia, USA, note that “[t]hese results appear favorable and are approximately comparable to our expectations with immunotherapy in younger patients.”